10X Genomics Inc（TXG）股票分析

$71.550

+1.846 (+2.58%)收盘时

Loading chart…

最高: 71.830
开盘: 68.940
成交量加权均价: 70.30
成交量: 2.23M
市值: 2.38B
最低: 67.520
成交额: 156.61M
企业价值/息税折旧摊销前利润（TTM）: -8.95

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.

www.10xgenomics.com

估值指标

10X Genomics Inc（TXG）当前预期市盈率为 -9.54，5 年平均预期市盈率为 -46.23。

预期市盈率

合理

5 年均值 P/E

-46.23

当前P/E

-9.54

高估

39.35

低估

-131.82

预期 EV/EBITDA

合理

5 年均值 EV/EBITDA

-442.73

当前EV/EBITDA

-8.95

高估

1320.89

低估

-2206.36

预期市销率

合理

5 年均值 P/S

8.44

当前P/S

2.27

高估

14.69

低估

2.20

Alphio AI 对 TXG 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。

乐

乐观

乐观 · 25%TXG

$7.67

情景价格

基

基准

基准 · 50%TXG

$7.57

情景价格

悲

悲观

悲观 · 25%TXG

$6.64

情景价格

持有 TXG 的大户

A

ARK Investment Management LLC

+ 持有TXG

+14.31%

3个月收益率

H

Harvard Management Company, Inc.

+ 持有TXG

+9.53%

3个月收益率

D

Davy Global Fund Management Limited

+ 持有TXG

+8.73%

3个月收益率

H

Hillsdale Investment Management Inc.

+ 持有TXG

+7.06%

3个月收益率

S

Sprott Inc.

+ 持有TXG

-0.63%

3个月收益率

B

Baker Steel Capital Managers LLP

+ 持有TXG

-0.67%

3个月收益率

事件时间线

2026-10-07 (ET)

09:30:00

10x Genomics Partners with Fred Hutchinson Cancer Center for Multi-Project Research

2026-10-06 (ET)

12:30:00

10x Genomics Shares Drop 13.4% to $84.67

2026-09-29 (ET)

09:30:00

10x Genomics Announces First Commercial Shipments of Atera Platform

2026-09-24 (ET)

12:30:00

10x Genomics Stock Rises 7.6% to $81.33

2026-09-10 (ET)

09:30:00

10x Genomics Integrates Lunit's AI Pathology Platform

查看更多事件

资讯

查看更多资讯

TXG 常见问题 —— 由 Alphio AI 解答

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

社区

分享你对 TXG 的看法

basedbackdraft2026/9/15

$TXG -- did you buy? I did not.

0 0

注册或登录后参与讨论

本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。